| Literature DB >> 35337182 |
Marija Ivanov1, Katarina Novović2, Milka Malešević2, Miroslav Dinić2, Dejan Stojković1, Branko Jovčić2,3, Marina Soković1.
Abstract
The rising incidence of antibiotic resistant microorganisms urges novel antimicrobials development with polyphenols as appealing potential therapeutics. We aimed to reveal the most promising polyphenols among hesperetin, hesperidin, naringenin, naringin, taxifolin, rutin, isoquercitrin, morin, chlorogenic acid, ferulic acid, p-coumaric acid, and gallic acid based on antimicrobial capacity, antibiofilm potential, and lack of cytotoxicity towards HaCaT, and to further test its antivirulence mechanisms. Although the majority of studied polyphenols were able to inhibit bacterial growth and biofilm formation, the most promising activities were observed for rutin. Further investigation proved rutin's ability to prevent/eradicate Pseudomonas aeruginosa and MRSA urinary catheter biofilms. Besides reduction of biofilm biomass, rutin antibiofilm mechanisms included reduction of cell viability, exopolysaccharide, and extracellular DNA levels. Moderate reduction of bacterial adhesion to human keratinocytes upon treatment was observed. Rutin antivirulence mechanisms included an impact on P. aeruginosa protease, pyocyanin, rhamnolipid, and elastase production and the downregulation of the lasI, lasR, rhlI, rhlR, pqsA and mvfR genes. Rutin also interfered with membrane permeability. Polyphenols could repress antibiotic resistant bacteria. Rutin has shown wide antimicrobial and antibiofilm capacity employing a range of mechanisms that might be used for the development of novel antimicrobials.Entities:
Keywords: antibiofilm activity; antibiotic resistance; antimicrobial activity; bacteria; cytotoxicity; mechanism of activity; polyphenols; rutin; virulence
Year: 2022 PMID: 35337182 PMCID: PMC8952364 DOI: 10.3390/ph15030385
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Antibacterial potential of selected polyphenols; results are expressed in mg/mL.
| Bacteria | Hesperetin | Hesperidin | Naringenin | Naringin | Taxifolin | Rutin | Isoquercitrin | Morin | Chlorogenic Acid | Ferrulic Acid | Gallic Acid | Streptomycin | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | 0.5 | 0.5 | 0.25 | 0.5 | 0.25 | 0.5 | 0.5 | 0.12 | 0.5 | 0.5 | 0.5 | >1 | 0.1 | |
| MBC | 1 | 1 | 0.5 | 1 | 0.5 | 1 | 1 | 0.25 | 1 | 1 | 1 | >1 | 0.8 | |
| MIC | 0.5 | 0.5 | 0.25 | 0.25 | 0.25 | 0.5 | 0.25 | 0.12 | 0.5 | 0.5 | 0.5 | >1 | 0.05 | |
| MBC | 1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 0.5 | 0.25 | 1 | 1 | 1 | >1 | 0.1 | |
| MIC | 1 | 1 | 1 | >1 | 1 | 0.5 | 0.25 | 1 | 1 | 1 | 0.5 | 1 | >1 | |
| MBC | 1 | 1 | 1 | >1 | >1 | 0.5 | 0.25 | 1 | >1 | 1 | 1 | 1 | >1 | |
| MIC | >1 | >1 | 0.5 | >1 | 0.5 | >1 | >1 | 0.25 | >1 | >1 | >1 | >1 | 0.1 | |
| MBC | >1 | >1 | 1 | >1 | 1 | >1 | >1 | 0.5 | >1 | >1 | >1 | >1 | 0.2 | |
| MIC | >1 | >1 | 1 | >1 | 1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | 1 | |
| MBC | >1 | >1 | >1 | >1 | 1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | >1 | |
| MIC | 0.5 | 0.5 | 0.5 | >1 | 0.5 | 0.5 | 0.25 | 0.5 | 1 | 0.5 | 0.5 | 0.5 | >1 | |
| MBC | 0.5 | 0.5 | 0.5 | >1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 1 | >1 | |
| MIC | 0.5 | 0.5 | 0.5 | >1 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 0.5 | 0.5 | 0.5 | >1 | |
| MBC | 0.5 | 0.5 | 0.5 | >1 | 0.5 | 0.5 | 0.5 | 0.5 | >1 | 0.5 | 0.5 | 0.5 | >1 | |
| MIC | 1 | 1 | 0.25 | >1 | 1 | 1 | 0.5 | 0.5 | >1 | 1 | 1 | 1 | >1 | |
| MBC | 1 | 1 | 0.5 | >1 | 1 | 1 | 1 | 1 | >1 | 1 | 1 | 1 | >1 | |
| MIC | >1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | >1 | 1 | 1 | 1 | >1 | |
| MBC | >1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | >1 | 1 | 1 | 1 | >1 | |
| MIC | 1 | 1 | 1 | >1 | 1 | 0.5 | 0.5 | 0.5 | 1 | 1 | 1 | 0.5 | >1 | |
| MBC | 1 | 1 | 1 | >1 | 1 | 1 | 0.5 | 1 | >1 | 1 | 1 | 1 | >1 | |
| MIC | >1 | >1 | >1 | >1 | >1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | >1 | |
| MBC | >1 | >1 | >1 | >1 | >1 | 1 | 1 | >1 | >1 | 1 | 1 | >1 | >1 |
Figure 1Formation of P. aeruginosa IBRS P001 biofilm after treatment with polyphenols. The error bars indicate standard deviations. The asterisks represent statistical significance *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, ****, p ≤ 0.0001, the data are presented as mean ± SD.
Cytotoxicity of examined compounds towards HaCaT cell line, represented as IC50 (compound concentration that inhibited 50% of the cell growth) in mg/mL.
| Polyphenol | IC50 (mg/mL) |
|---|---|
| Hesperetin | >1 |
| Hesperidin | >1 |
| Naringenin | 0.528 ± 0.047 |
| Naringin | >1 |
| Taxifolin | 0.495 ± 0.047 |
| Rutin | >1 |
| Isoquercitrin | >1 |
| Morin | 0.347 ± 0.016 |
| Chlorogenic acid | 0.279 ± 0.008 |
| Ferulic acid | >1 |
| p-coumaric acid | >1 |
| Gallic acid | <0.080 |
Figure 2Impact of rutin on biofilm prevention and biofilm eradication on catheter biofilm model. P. aeruginosa IBRS P001 cell attachment on catheter surface (A); 24 h old P. aeruginosa biofilm (B); MRSA IBRS MRSA011 cell attachment on catheter surface (C) and 24 h old MRSA biofilms (D) upon treatment with rutin. The asterisks represent statistical significance **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001, the data are presented as mean ± SD.
Figure 3P. aeruginosa IBRS P001 (A) and MRSA IBRS MRSA011 (B) adhesion to HaCaT cells upon treatments with rutin (%). The data are presented as mean ± SD.
Figure 4Different modes of rutin acting on P. aeruginosa IBRS P001 biofilm formation: impact on viability of cells in biofilm (A); production of exopolysaccharides (B) and eDNA production (C). The asterisks represent statistical significance **, p ≤ 0.01; ***, p ≤ 0.001, the data are presented as mean ± SD.
Figure 5Different mechanisms of P. aeruginosa IBRS P001 24 h old biofilms eradication: impact on biofilm mass (A); interference with cell viability (B); exopolysaccharide (C) and eDNA (D) production. The asterisks represent statistical significance *, p ≤ 0.05; the data are presented as mean ± SD.
Figure 6Rutin (0.5 MIC, 0.250 mg/mL) antivirulence mechanisms towards P. aeruginosa IBRS P001: impact on protease (A); pyocyanin (B); rhamnolipid (C) and elastase (D) production. The asterisks represent statistical significance ***, p ≤ 0.001; the data are presented as mean ± SD.
Figure 7Relative mRNA levels of different P. aeruginosa IBRS P001 virulence associated genes upon treatment with rutin (0.5 MIC, 0.250 mg/mL). The asterisks represent statistical significance **, p ≤ 0.01; ***, p ≤ 0.001, the data are presented as mean ± SD.
Figure 8Leakage of intracellular material after treatment with rutin (MIC) as detected for P. aeruginosa IBRS P001 nucleic acids (A) and proteins (B), as well as for MRSA IBRS MRSA 011 nucleic acids (C) and proteins (D). The data are presented as mean ± SD.
List of bacterial strains used in the study and the corresponding antibiotic resistance.
| Strain | Resistance | Reference |
|---|---|---|
| Methicillin-resistant | cefoxitin | [ |
| penicillin, ampicillin, amoxicillin, tetracycline, neomycin, gentamicin, ceftriaxone | [ | |
| imipenem, meropenem, gentamycin | [ | |
| penicillin, ampicillin, amoxicillin, tetracycline, neomycin, gentamicin, ceftriaxone | [ | |
| amoxicillin/clavulanate, ampicillin/sulbactam, | [ | |
| amoxicillin/clavulanate, ampicillin/sulbactam, | [ | |
| imipenem, meropenem, ciprofloxacin, levofloxacin, amikacin, gentamicin, tobramycin, trimethoprim/sulfamethoxazole, colistin | [ | |
| imipenem, meropenem, colistin | [ | |
| ampicillin/clavulanate, piperacillin/tazobactam, cefazolin, ceftriaxone, cefepime, aztreonam, ertapenem, imipenem, meropenem, ciprofloxacin, moxifloxacin, gentamicin, tobramycin, nitrofurantoin | [ | |
| tetracycline, chloramphenicol, ciprofloxacin, levofloxacin, trimethoprim/sulfamethoxazole | [ | |
| tetracycline, quinolones, colistin | [ |
Primers used for RT-qPCR analysis.
| Gene | Primer Direction | Sequence (5′-3′) | Amplicon Size (bp) | Reference |
|---|---|---|---|---|
|
| Forward | GCGTGCTCAAGTGTTCAAGG | 125 | [ |
| Reverse | GGGCTTCAGGAGTATCTTCCTGG | |||
|
| Forward | CTGTGGATGCTCAAGGACTAC | 133 | [ |
| Reverse | AACTGGTCTTGCCGATGG | |||
|
| Forward | CCATCCGCAAACCCGCTACATC | 151 | [ |
| Reverse | CTCCCAGACCGACGGATCGCTCGGC | |||
|
| Forward | GGGCGTGTTCGCCGTCCTGG | 143 | [ |
| Reverse | GGTATCGCTCCAGCCAGGCCTTG | |||
|
| Forward | GACCGGCTGTATTCGATTC | 74 | [ |
| Reverse | GCTGAACCAGGGAAAGAAC | |||
|
| Forward | GTCGGGACGGCTACAAGGTCG | 129 | [ |
| Reverse | GATTGCGCGGACCCTTGTTGAG | |||
|
| Forward | GCAACTATCAACCAGCTGGTG | 231 | [ |
| Reverse | GCTGTGCTCTTGCAGGTTGTG |